Cancer Cure Now

Conflict Of Interest

Maintenance of cancer as a chronic disease, rather than complete cure, provides the greatest income to agencies of the cancer industry, to the point where there is a conflict of interest between the financial wellbeing of the cancer industry and the health of cancer patients.

If a cheap, permanent cancer cure was unveiled, it would be a major financial blow to the medical-industrial complex. The entire government regulatory system which is supposed to safeguard public health is stacked in favor of large pharmaceutical companies.

Natural cancer treatments cannot produce large profits for drug companies because they cannot be patented. Large profits are required to fund the expensive clinical trials needed for FDA drug approval. Therefore, natural treatments never receive FDA approval to treat diseases. American physicians are only allowed to prescribe treatments which bear the FDA stamp of approval. Those who prescribe treatments which are not FDA approved can be sued for malpractice or lose their licenses.

Many institutions supposedly dedicated to finding cancer cures have strong ties to a variety of large industries. For example, the American Cancer Society, America's largest volunteer cancer agency, spends approximately only a quarter of its massive budget on research, according to medical researcher Dr. Samuel S. Epstein, with the bulk of monies collected going to administrative costs.

It is closely affiliated with industrial manufacturers, pharmaceutical companies and the mammography industry, and has repeatedly lobbied against environmental laws to limit public exposure to carcinogenic industrial toxins and pesticides.

In 1992, The Chronicle of Philanthropy reported that the ACS was "more interested in accumulating wealth than in saving lives." While studies on conventional cancer treatments are plentiful, one must beware of their accuracy.

Because of the large profit potential of new drugs, the temptation always exists to alter or misinterpret statistics in favor of the drug company. Unfortunately, the possibility of scientific fraud surrounding drug research must always be considered, not only in the area of cancer drugs but also in studies of other widely-used medications such as anti-depressants and cholesterol-lowering drugs.